BridgeBio · 2 months ago
Director, Government Affairs
Washington DC
Full-time
Hybrid
Director/Executive
$215K/yr - $270K/yr
6+ years expBridgeBio is a biotech company focused on developing life-changing medicines for patients with unmet needs. The Director of Government Affairs will represent the company in federal policy discussions, craft and execute engagement strategies, and build relationships with key policymakers to advance BridgeBio’s priorities.
BiotechnologyHealth CareLife ScienceMedicalPharmaceutical
Responsibilities
Support the development and execution of BridgeBio’s federal government affairs strategy, representing the company before Congress, federal agencies, and relevant industry groups to advance BridgeBio’s policy priorities
Develop and maintain strong relationships and engage with federal legislators, staff, and regulators to ensure BridgeBio can have a voice in important policy discussions and decisions that impact drug development, innovation, and access to treatments
Monitor, forecast, and interpret emerging legislative and policy developments to anticipate potential impacts on BridgeBio’s business, pipeline, and patients, advising internal colleagues on proactive engagement strategies
Partner with internal stakeholders (e.g., Regulatory Affairs, Commercial, Corporate Communications, Patient Advocacy, and affiliate teams) to integrate government affairs insights into business and pipeline planning for early-stage, late-stage, and product-launch efforts
Prepare policy briefings, materials, and talking points to support company leadership and affiliate teams
Contribute to the company’s Political Action Committee (PAC) strategy and engagement, ensuring alignment with policy goals
Qualification
Required
6+ years of experience within Congress, a pharma/biotech policy advocacy organization, or government relations
Bachelor's degree or higher in public policy, law, political science, or related experience
Strong understanding of legislative and regulatory processes and a track record of building and sustaining top-tier relationships with key federal policymakers
Knowledge of the health care system and key policies relevant to the biopharmaceutical sector
Established relationships within the U.S. Congress and federal officials
Highly organized and self-directed, with the ability to manage multiple priorities and work effectively in a fast-paced environment
A natural collaborator and communicator who can translate complex policy issues into clear, actionable insights for internal teams
A passion for celebrating science and helping patients
Benefits
401K with 100% employer match on first 3% & 50% on the next 2%
Employee stock purchase program
Pre-tax commuter benefits
Referral program with $2,500 award for hired referrals
Comprehensive health care with 100% premiums covered - no cost to you and dependents
Mental health support via Spring Health (6 therapy sessions & 6 coaching sessions)
Hybrid work model - employees have the autonomy in where and how they do their work
Unlimited flexible paid time off - take the time that you need
Paid parental leave - 4 months for birthing parents & 2 months for non-birthing parents
Flex spending accounts & company-provided group term life & disability
Subsidized lunch via Forkable on days worked from our office
People are part of our growth and success story - from discovery to active drug trials and FDA pipelines, there are endless opportunities for skill development and internal mobility
We provide career pathing through regular feedback, continuous education and professional development programs via LinkedIn Learning, LifeLabs, Spring Health & BetterUp Coaching
We celebrate strong performance with financial rewards, peer-to-peer recognition, and growth opportunities
Company
BridgeBio
BridgeBio focuses on the development and commercialization of precision medicines for various genetic diseases and cancers.
201-500 employees
Funding
Current Stage
Public CompanyTotal Funding
$4.9BKey Investors
Blue OwlQatar Investment AuthorityKohlberg Kravis Roberts
2026-01-16Post Ipo Debt· $550M
2025-02-25Post Ipo Debt· $500M
2024-03-04Post Ipo Equity· $250M
Leadership Team
Justin To
CEO, Skeletal Dysplasias (QED Therapeutics)
Neil Kumar
CEO and Founder
Recent News
BioWorld Financial Watch
2026-01-17
Company data provided by crunchbase